New data from AVONELLE-X and SALWEEN studies of Vabysmo shows disease control and durability in nAMD over 4 years, with significant vision improvements in difficult-to-treat forms of the disease. Vabysmo was well-tolerated with a consistent long-term safety profile. The results were presented at the 25th Euretina Congress in Paris, France. Vabysmo has been approved in over 100 countries for nAMD and diabetic macular edema, with more than eight million doses distributed globally since 2022. Vabysmo targets two signaling pathways linked to vision-threatening retinal conditions, stabilizing blood vessels to prevent further vision loss. In the AVONELLE-X trial, patients with nAMD maintained disease control and durability over 4 years, with nearly 80% on extended dosing by the study’s end. The SALWEEN study showed that over 60% of difficult-to-treat nAMD patients had no damaging lesions, with significant vision improvements. Vabysmo demonstrated a consistent safety profile in nAMD. Roche has a diverse retina pipeline targeting various eye diseases, offering innovative treatments like Susvimo and Vabysmo. The company is committed to sustainability and improving global healthcare through scientific excellence and personalized medicine. The AVONELLE-X trial showed that disease control and durability were maintained over 4 years in patients with nAMD, with nearly 80% on extended dosing by study end. In the SALWEEN study, over 60% of patients with difficult-to-treat nAMD had no signs of damaging lesions and saw clinically meaningful vision improvements. Vabysmo was found to be well tolerated with a consistent long-term safety profile in both studies.

Read more at 1. Long-term trial shows disease control and durability in nAMD patients – GlobeNewswire
2. SALWEEN study reveals positive results for difficult-to-treat nAMD form – GlobeNewswire
3. Vabysmo demonstrates long-term safety profile in nAMD studies – GlobeNewswire: New data for Roche’s Vabysmo reinforce its efficacy, safety